Advertisement
Advertisement
U.S. markets open in 6 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.07-0.08 (-1.55%)
At close: 04:00PM EST
5.07 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.15
Open5.10
Bid0.00 x 800
Ask0.00 x 800
Day's Range4.93 - 5.15
52 Week Range4.93 - 14.40
Volume581,541
Avg. Volume254,459
Market Cap140.065M
Beta (5Y Monthly)-0.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NXTC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NextCure, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Rating
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • GlobeNewswire

    NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

    BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data in oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia, and on a virtual platform. The data come from preclinical research studies in collaboration with Emory Unive

  • GlobeNewswire

    NextCure to Present at The JMP Securities Hematology and Oncology Summit

    BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday December 7th at 11:40 am ET. A live audio webcast will be available through the Investors section of the company’s website

  • GlobeNewswire

    NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

    BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th. An audio webcast of the pre-recorded fireside chat will be available today at 10 a.m. ET through the Investors section of th

Advertisement
Advertisement